

Characteristics, temporal trends and outcomes of intravenous thrombolysis in Chinese patients aged >80 years who had a stroke

Changsheng Li ^{1,2,3}, Yingyu Jiang,^{1,3,4} Hong-Qiu Gu ^{1,3,4}, Meng Wang ^{1,3,4}, Zimo Chen ^{1,3}, Xin Yang,^{3,4} Qi Zhou ³, Xia Meng,^{1,3} Chunjuan Wang,^{1,3,4} Zixiao Li ^{1,3,4}

To cite: Li C, Jiang Y, Gu H-Q, *et al.* Characteristics, temporal trends and outcomes of intravenous thrombolysis in Chinese patients aged >80 years who had a stroke. *Stroke & Vascular Neurology* 2024;**0**:doi:10.1136/svn-2024-003427

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/svn-2024-003427>).

CL and YJ contributed equally.

Received 25 May 2024
Accepted 3 October 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Zixiao Li;
lizixiao2008@hotmail.com

Dr Chunjuan Wang;
chuner_wang@126.com

ABSTRACT

Background and purpose To date, no large cohort study has investigated the effects of intravenous thrombolysis (IVT) in Chinese patients aged over 80 years who had a stroke. This study aimed to assess the trends in the use of alteplase, the clinical characteristics and the outcomes of Chinese patients aged above 80 years who had an acute ischaemic stroke.

Methods Data for this analysis were obtained from the China Stroke Center Alliance programme, a nationwide, multicentre, prospective registry encompassing 1751 hospitals across 31 provinces, covering the period from 1 January 2018 to 14 December 2022. The primary outcome was defined as a modified Rankin Scale (mRS) Score of 0–2 at discharge. Secondary outcomes included an mRS Score of 0–1 and independent ambulation on discharge. Safety outcomes assessed were in-hospital mortality and symptomatic intracranial haemorrhage (sICH).

Results Out of 30 902 patients over 80 years old who qualified for thrombolysis, 8673 (median age (IQR), 84 (82–87) years) received alteplase treatment. Patients administered alteplase demonstrated improved short-term functional outcomes, such as an mRS Score of 0–2 (adjusted OR (aOR) 1.12, 95% CI, 1.06 to 1.18, $p<0.001$), an mRS Score of 0–1 (aOR 1.14, 95% CI, 1.08 to 1.19, $p<0.001$) and independent ambulation at discharge (aOR 1.14, 95% CI, 1.08 to 1.20, $p<0.001$). Moreover, no significant increase was observed in the risk of in-hospital mortality (aOR 1.12, 95% CI, 0.93 to 1.35; $p=0.23$). However, the risk of sICH was significantly higher among patients treated with alteplase (aOR 3.22, 95% CI, 2.77 to 3.75; $p<0.001$).

Conclusions IVT with alteplase in elderly patients who had a stroke resulted in improved short-term functional outcomes without elevating the risk of in-hospital mortality. Nonetheless, this population remains at a higher risk of sICH.

INTRODUCTION

Stroke remains the leading cause of mortality in China,^{1–3} with the nation having the highest lifetime stroke risk among individuals aged 25 years and older.⁴ Despite the Chinese government's efforts to implement comprehensive stroke prevention strategies, stroke

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Currently, neither China nor the USA imposes an upper age limit for administering intravenous thrombolysis (IVT) to patients who had an ischaemic stroke. However, the Chinese Food and Drug Administration continues to restrict the use of alteplase for those over 80 years old. Furthermore, no large-scale cohort studies have evaluated the application of IVT in Chinese patients above the age of 80 in real-world clinical settings.

WHAT THIS STUDY ADDS

⇒ This nationwide cohort study of patients over 80 years who had an ischaemic stroke reveals that the use of IVT rose by 13.6% between 2018 and 2022. Elderly patients who received alteplase therapy showed improved functional outcomes at discharge compared with those who did not, without experiencing a higher rate of in-hospital mortality.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The results of this study provide stronger evidence supporting the application of alteplase in patients over 80 years who had a stroke, potentially influencing future research, clinical practices and policy guidelines.

prevalence continues to rise alongside population growth.^{3–5} Additionally, stroke incidence increases with age. In 2019, the prevalence of ischaemic stroke was 6.58% among individuals aged 65–69 years, while in those aged 80 and above, the prevalence was notably higher at 12.81%.⁶ Acute ischaemic stroke in the elderly leads to more significant neurological deficits compared with younger individuals, resulting in higher rates of disability and mortality.⁷ With the rapidly ageing population in China, the number of individuals aged 80 years and older, which was 26 million in 2019, is expected to surge to 115 million by 2050.⁸ This demographic shift makes it crucial to

address strategies for reducing disability in patients over 80 years who had a stroke.

Intravenous thrombolysis (IVT) with alteplase has been shown to be an effective treatment for acute ischaemic stroke, reducing disability by promoting reperfusion.^{9 10} However, its use in older patients has historically been limited due to concerns about age. In 2013 and 2014, the American Heart Association¹¹ and the Chinese Academy of Neurology¹² removed age >80 years as a contraindication for IVT within 3 hours of symptom onset. By 2018, the recommended time window for IVT was extended to 4.5 hours.^{13 14} As guidelines continue to evolve both domestically and internationally, a growing number of elderly patients are becoming eligible for IVT. Consequently, in the USA, IVT usage in elderly patients saw a significant increase from 2008 to 2009 to 2016–2017.¹⁵ However, there has yet to be a large cohort study examining the use of IVT in Chinese patients over 80 years old,^{16 17} and the trends in IVT use among this population remain underexplored. A thorough understanding of IVT use in elderly patients who had a stroke in China is essential for guiding healthcare providers and policymakers in optimising treatment strategies for this demographic.

The objective of this study was to analyse data from a nationwide registry to assess in-hospital outcomes in elderly patients who had a stroke who received IVT with alteplase and to evaluate trends in IVT treatment rates among patients older than 80 years compared with those 80 years or younger.

METHODS

The China Stroke Center Alliance (CSCA) programme is a large-scale, nationwide, multicentre, voluntary and prospective registry designed to promote continuous quality improvement in the care of patients who had a stroke. The details of the programme's design and data collection methods have been thoroughly documented in earlier studies.¹⁸ This initiative was open to both secondary and tertiary hospitals across China. Trained staff at each participating hospital collected data using a web-based patient management system developed by the Medicine Innovation Research Center. Data analysis was conducted by the China National Clinical Research Center for Neurological Diseases. Participating hospitals agreed to use anonymised data for research purposes and to assess the quality of care provided. Collected data at the time of admission included demographic factors (such as sex, age and body mass index (BMI)), as well as clinical risk factors, including smoking status, alcohol use, hypertension, diabetes, dyslipidaemia, myocardial infarction, peripheral arterial disease and history of stroke or transient ischaemic attack (TIA). Additionally, the National Institutes of Health Stroke Scale (NIHSS) Score, stroke severity, onset-to-door time (ODT), onset-to-treatment time, door-to-needle time, alteplase dosage, medical history, hospital classification (secondary or tertiary) and

geographic region (eastern, central, or western China) were recorded.

Patient population

This study involved patients who had an ischaemic stroke treated at 1751 hospitals participating in the CSCA between 1 January 2018 and 14 December 2022. Eligibility was determined based on the occurrence of stroke symptoms within 4.5 hours and the absence of any absolute contraindications for thrombolysis, as outlined in the guidelines.¹¹ Patients were excluded if they had undergone thrombectomy, received alternative thrombolytic agents, underwent intra-arterial thrombolysis or had incomplete data regarding NIHSS scores, prior modified Rankin Scale (mRS) scores, key time points (such as door-to-needle or onset-to-treatment time), alteplase dosage or in-hospital outcomes.

Patient and public involvement

No patient involved.

Outcome measurement

The primary outcome was the mRS, which scores from 0 (normal) to 6 (death), with an mRS Score of 0–2 at discharge. Secondary outcomes included achieving an mRS Score of 0–1 and the ability to walk independently on discharge. Safety measures encompassed in-hospital mortality and symptomatic intracranial haemorrhage (sICH), following the National Institute of Neurological Disorders and Stroke criteria, which defines sICH as any parenchymal haemorrhage detected via CT or MRI, accompanied by clinical deterioration within 36 hours of treatment initiation.⁹ To assess treatment effects in elderly patients with ischaemic stroke, predefined subgroups based on sex, NIHSS-classified stroke severity (ranging from mild (0–4), moderate,^{5–15} moderate to severe^{16–20} to severe (>20)), prior stroke or TIA, diabetes and atrial fibrillation were analysed. Additionally, outcomes were stratified into three categories based on the ODT: group 1 (ODT ≤ 2 hours), group 2 (2–3.5 hours) and group 3 (ODT > 3.5 hours).

Statistical analysis

Continuous variables were expressed as medians, while categorical variables were summarised using frequencies and percentages. Logistic regression models were applied to evaluate in-hospital outcomes among elderly patients who received alteplase compared with those who did not. To address baseline differences between the two groups, inverse probability weighting (IPTW) was employed to generate propensity scores.^{19 20} Sensitivity analyses were conducted using 1:1 propensity score matching to assess the robustness of thrombolysis outcomes. A caliper width of 0.2 SD was used, ensuring that standardised differences were maintained below 0.1 for balance. The models were adjusted for several covariates, including sex, age, hospital type, BMI, relevant risk factors (such as prior stroke or TIA, and atrial fibrillation) and medical history (use of antiplatelet agents and statins). For in-hospital outcomes

stratified by ODT, multivariable logistic regression models were used, adjusting for statistically significant covariates in each group.

Subgroup analyses were performed to evaluate the interaction effects of treatment on primary outcomes across specific patient subgroups using multivariable logistic regression. The impact of prior anticoagulant or antithrombotic therapy on hospital outcomes in patients over 80 years of age receiving thrombolytic therapy was also examined. Previous antithrombotic therapy refers to taking one or more antithrombotic agents continuously for at least 2 weeks within the 6 months before the condition started.

Temporal trends in IVT use from 2018 to 2022 were evaluated through Cochran-Armitage trend tests.

Outcome variables with missing data were excluded from the analysis. Sensitivity analyses were performed to compare baseline characteristics between populations with and without missing data.

Two-sided p values of less than 0.05 were deemed statistically significant. Given the large sample size, small differences might have reached statistical significance without clinical relevance, prompting the calculation of absolute standardised differences (ASDs). An ASD greater than 10% was considered indicative of significant imbalance.^{21 22} All statistical analyses were conducted using SAS V.9.4.

RESULTS

Baseline characteristics

After excluding ineligible cases, the study included 212814 patients who had an ischaemic stroke from 1751 hospitals between 1 January 2018 and 14 December 2022. Among these, 30902 patients were aged over 80 years, with 8673 receiving alteplase treatment and 22229 not receiving it (figure 1 and online supplemental eTable 1). For patients over 80 years old (table 1), the median age of those treated with alteplase was 84 years (IQR, 82.0–87.0), with a higher proportion of women (52.7%, n=4570). The median door-to-needle time was 44.2 min (IQR, 29.0–65.0 min). Compared with those not treated with alteplase, patients who received the treatment had more severe strokes (median NIHSS Score 9 vs 5, ASD=60.0%), a lower BMI (median 21.7 (IQR, 19.2–24.2) vs 22.8 (IQR, 20.8–24.8), ASD=29.1%), a higher prevalence of atrial fibrillation (20.7% vs 15.8%, ASD=12.9%), a lower history of stroke or TIA (27.0% vs 37.5%, ASD=22.6%), shorter ODTs (median 1.5 hours (IQR, 0.9–2.2) vs 1.9 hours (IQR, 1.0–3.0), ASD=29.7%) and lower usage rates of antiplatelet agents (17.9% vs 24.2%, ASD=14.6%) and statins (15.4% vs 21.0%, ASD=14.2%). After adjustment via propensity score matching, baseline characteristics between the two groups achieved balance, except for baseline NIHSS and pre-stroke mRS 0–2 (online supplemental eTable 2).




Figure 1 Flowchart for patient selection. BMI, body mass index; CSCA, China Stroke Center Alliance; EVT, endovascular thrombectomy; IVT, intravenous thrombolysis; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic intracranial haemorrhage; tPA tissue-type plasminogen activator.

Table 1 Baseline characteristics of patients aged>80 years according to assigned treatment

Variables	With alteplase (n=8673)	Without alteplase (n=22 229)	P value	Absolute standard difference (%)
Female, n, (%)	4570 (52.7)	11 518 (51.8)	0.17	1.8
Age, years, median (IQR)	84.0 (82.0–87.0)	84.0 (82.0–87.0)	<0.001	11.4
BMI, median (IQR), kg/m ²	21.7 (19.2–24.2)	22.8 (20.8–24.8)	<0.001	29.1
Current smoking	822 (9.5)	1985 (8.9)	0.13	1.9
Drinking	954 (11.0)	2500 (11.2)	0.54	0.8
Prior stroke or TIA	2340 (27.0)	8329 (37.5)	<0.001	22.6
Hypertension	5555 (64.0)	14 181 (63.8)	0.68	0.5
Diabetes mellitus	1305 (15.0)	3574 (16.1)	0.03	2.8
Dyslipidaemia	352 (4.1)	1382 (6.2)	<0.001	9.8
Myocardial infarction	255 (2.9)	574 (2.6)	0.08	2.2
Atrial fibrillation	1797 (20.7)	3504 (15.8)	<0.001	12.9
PAD	116 (1.3)	522 (2.3)	<0.001	7.5
Insurance, n, (%)				11.1
NRCMS	2473 (28.5)	7342 (33.0)		
Self-payment	306 (3.5)	654 (2.9)		
UEBMI	2859 (33.0)	6961 (31.3)		
URBMI	2689 (31.0)	6247 (28.1)		
Other	346 (4.0)	1025 (4.6)		
Family income per month, n, (%), ¥				7.5
≤3000	2091 (24.1)	6005 (27.0)		
>3000	1855 (21.4)	4279 (19.2)		
Unclear	4727 (54.5)	11 945 (53.7)		
Prior mRS 0–2, n, (%)	6870 (79.2)	17 267 (77.7)	0.003	3.7
NIHSS Score at admission, median (IQR)	9.0 (4.0–15.0)	4.0 (2.0–10.0)	<0.001	60.0
Stroke severity, n, (%)			<0.001	54.8
NIHSS≤4	2177 (25.1)	11 202 (50.4)		
NIHSS≥5 to ≤15	4373 (50.4)	7951 (35.8)		
NIHSS>15 to ≤20	1210 (14.0)	1664 (7.5)		
NIHSS>20	913 (10.5)	1412 (6.4)		
Onset-to-door time (hour, median, IQR)	1.5 (0.9–2.2)	1.9 (1.0–3.0)	<0.001	29.7
Onset to treatment time				NA
<3 hours	6037 (69.6)	NA		
≥3 hours	2636 (30.4)	NA		
Door-to-needle time (min, median, IQR)	44.2 (29.0–65.0)	NA		
Time segments				NA
≤60 min	6154 (71.0)	NA		
>60 min	2519 (29.0)	NA		
Alteplase dose, mg, median (IQR)	0.9 (0.6–0.9)	NA		NA
Medical history, n, (%)				
Anticoagulant agents	257 (3.0)	973 (4.4)	<0.001	7.5
Antiplatelet agents	1683 (18.0)	5994 (23.9)	<0.001	14.6
Antihypertension agents	4291 (45.9)	12 127 (48.4)	<0.001	5.1
Glucose-lowering agents	1022 (10.9)	3153 (12.6)	<0.001	5.2
Statins	1442 (15.4)	5228 (20.9)	<0.001	14.2

Continued

Table 1 Continued

Variables	With alteplase (n=8673)	Without alteplase (n=22 229)	P value	Absolute standard difference (%)
Hospital characteristics, n, (%)				
Hospital grade			<0.001	10.8
Secondary	4143 (44.3)	12 440 (49.7)		
Tertiary	5212 (55.7)	12 610 (50.3)		
Hospital region			<0.001	4.9
Eastern	3497 (37.4)	9949 (39.7)		
Central	3303 (35.3)	8615 (34.4)		
Western	2555 (27.3)	6486 (25.9)		

BMI, body mass index; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NRCMS, new rural cooperative medical scheme; PAD, peripheral arterial disease; TIA, transient ischaemic attack; UEBMI, urban employee basic medical insurance; URBMI, urban resident basic medical insurance.

The main reason for not administering alteplase thrombolysis was exceeding the 4.5-hour thrombolysis window for treatment (11 765 of the 22 299 patients, 52.9%, online supplemental eTable 3). Other reasons included patients or family members declining the recommendation (7091 of the 22 299 patients, 31.9%), hospital-related and other factors (208 of the 22 299 patients, 0.9%), economic reasons such as intravenous tissue-type plasminogen activator not being covered by health insurance (183 of the 22 299 patients, 0.9%) and unknown reasons (2992 of the 22 299 patients, 13.5%).

Patients with missing outcome data were excluded from the final analysis. Sensitivity analyses indicated no significant baseline differences between patients with and without missing data (online supplemental eTable 4).

In-hospital outcomes for elderly patients

A detailed comparison of outcome measures is shown in table 2. After adjusting for covariates using IPTW scores, elderly patients treated with alteplase had significantly better functional outcomes at discharge. Specifically, a higher proportion of patients achieved an mRS Score of 0–2 (55.5%, n=4815; adjusted OR (aOR) 1.12, 95% CI, 1.06 to 1.18, p<0.001), an mRS Score of 0–1 (43.3%, n=3743; aOR 1.14, 95% CI, 1.08 to 1.19, p<0.001) and independent ambulation (65.0%, n=5640; aOR 1.14, 95% CI, 1.08 to 1.20, p<0.001). However, patients treated with alteplase exhibited higher rates of sICH compared with those not treated (4.9% (n=423) vs 1.2% (n=273); aOR 3.22, 95% CI, 2.77 to 3.75, p<0.001). The

Table 2 Comparison of in-hospital outcomes in patients aged >80 years for stroke with or without alteplase treatment

Outcome variable	Outcome rates (%)		Odds ratio (95% CI)		
	With alteplase	Without alteplase	Unadjusted	IPTW*	PSM†
Primary outcome					
mRS 0–2 at discharge	4815 (55.5)	13 789 (62.0)	0.80 (0.76 to 0.84)	1.12 (1.06 to 1.18)	1.25 (1.16 to 1.34)
Secondary outcomes					
mRS 0–1 at discharge	3743 (43.3)	10 828 (48.7)	0.76 (0.73 to 0.80)	1.14 (1.08 to 1.19)	1.26 (1.17 to 1.35)
Independent ambulation at discharge	5640 (65.0)	15 935 (71.7)	0.73 (0.70 to 0.77)	1.14 (1.08 to 1.20)	1.22 (1.13 to 1.31)
Safety outcomes					
sICH‡	423 (4.9)	273 (1.2)	4.12 (3.53 to 4.81)	3.22 (2.77 to 3.75)	3.21 (2.64 to 3.90)
In-hospital mortality	203 (2.3)	292 (1.3)	1.80 (1.50 to 2.16)	1.12 (0.93 to 1.35)§	1.22 (0.99 to 1.50)¶

*Model adjusted for sex, age, body mass index, prior stroke or transient ischaemic attack, atrial fibrillation, NIHSS Score at admission, onset-to-door time, antiplatelet agents, statins, insurance and hospital characteristics by IPTW.

†Model adjusted potential residual confounders (NIHSS Score at admission and pre-stroke mRS 0–2) after PSM.

‡According to the National Institute of Neurological Disorders and Stroke criterion.

§P=0.23.

¶P=0.06.

IPTW, inverse probability-weighted score; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PSM, Propensity score matching; sICH, symptomatic intracranial haemorrhage.

incidence of in-hospital mortality was similar between the two groups (2.3% vs 1.3%, aOR 1.12, 95% CI, 0.93 to 1.35, $p=0.23$). Sensitivity analysis using propensity score matching yielded consistent results (table 2).

After adjusting for the statistically significant variables listed in online supplemental eTable 5 using a multivariate regression model, the results for in-hospital outcomes stratified by ODT are shown in online supplemental eTable 6. Compared with untreated patients, each treatment group had a better adjusted primary outcome (group 1, $p<0.001$; group 2, $p<0.001$; group 3, $p=0.002$) and independent ambulation (group 1, $p<0.001$; group 2, $p<0.0001$; group 3, $p=0.0043$). Otherwise, there was no difference in mRS 0–1 between patients treated with alteplase and those who were not (143 (39.8%) vs 1865 (48.3%], aOR 1.15, 95% CI, 0.89 to 1.49, $p=0.291$) in group 3 (ODT>3.5 hours). Patients who were treated with alteplase were more likely to have sICH regardless of ODT (group 1, $p<0.001$; group 2, $p<0.001$; group 3, $p<0.001$). There was no significant difference in in-hospital mortality rates between patients treated with alteplase and those who were not except for ODT≤2 hours in group 1 (2.8% vs 1.5%, aOR 1.32, 95% CI, 1.05 to 1.67, $p<0.001$).

Subgroup analysis

In the subgroup of patients with ischaemic stroke aged>90 years, thrombolysis with alteplase versus no alteplase demonstrated comparable treatment effects regarding the proportion achieving an mRS Score of 0–1 (aOR 1.19, 95% CI, 0.98 to 1.43, $p=0.07$), mRS Score of 0–2 (aOR 1.11, 95% CI, 0.93 to 1.34, $p=0.236$) and independent ambulation at discharge (aOR 1.04, 95% CI, 0.87 to 1.25, $p=0.660$). In contrast, the alteplase group showed a higher risk of haemorrhage (aOR 1.19, 95% CI, 1.78 to 5.37, $p<0.001$) without a significant difference in mortality in the hospital (aOR 1.30, 95% CI, 0.77 to 2.21, $p=0.327$) (online supplemental eTable 7).

As shown in figure 2, we performed exploratory subgroup analyses stratified by sex, stroke severity according to the NIHSS, previous stroke/TIA status, atrial fibrillation status and diabetes status by multivariate regression model. Overall, each characteristic tended to be associated with better functional outcomes with thrombolysis. However, there were interactions within three specific subgroups: atrial fibrillation, stroke severity, diabetes (p for interaction in each group<0.001). Patients with a history of atrial fibrillation (aOR 1.75, 95% CI, 1.51 to 2.03, $p<0.001$), moderate stroke (aOR 1.62, 95% CI, 1.49 to 1.76, $p<0.001$) or without diabetes (aOR 1.41, 95% CI, 1.32 to 1.51, $p<0.001$).




Figure 2 Subgroup analysis of the primary outcome in patients older than 80 years according to assigned treatment. NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischaemic attack.

95% CI, 1.35 to 1.51, $p < 0.001$) benefitted more from thrombolysis.

Covariates were corrected for age, sex and all statistically significant variables listed in online supplemental eTable 8, except for BMI. As a result, the findings regarding the impact of prior antithrombotic therapy on thrombolysis, which are detailed in online supplemental eTable 9, were adjusted accordingly. In elderly patients undergoing thrombolysis, no significant differences in functional outcomes (mRS scores of 0–1 and 0–2, and independent ambulation at discharge) were observed when comparing individuals with a history of antithrombotic therapy, regardless of the type of prior antithrombotic therapy:

antiplatelet alone, anticoagulant alone or a combination of both ($p > 0.05$ for all groups). Additionally, prior antithrombotic therapy did not increase the incidence of sICH or in-hospital mortality following thrombolysis in patients ($p > 0.05$ for all groups).

Temporal trends in IVT rates among potentially eligible patients

As demonstrated in figure 3, the rate of IVT increased over time in both age groups. For patients over 80 years old, IVT use rose from 22.1% in 2018 to 35.7% in 2022, while in younger patients, the increase was from 30.5% to 43.3% during the same period. The absolute growth




Figure 3 Temporal trends in rates of intravenous thrombolysis (IVT) use among potentially eligible patients from 2018 to 2022. Use rate of IVT with alteplase in all patients (A); use rate of IVT with alteplase in patients aged >80 years and 80 years and younger (B); use rate of IVT with alteplase by hospital grade (C) and use rate of IVT with alteplase by hospital region (D). Shading represents 95% CIs.

rates were similar between the groups (13.6% vs 12.8%). Despite starting at a lower baseline, the older cohort exhibited a higher average annual percentage increase in IVT usage compared with younger patients (12.5% vs 9.1%). All groups exhibited an increasing trend in thrombolysis rates, regardless of their level of hospitalisation or geographical location. Tertiary hospitals had a lower absolute growth rate than secondary hospitals (tertiary vs secondary, 10.8% vs 12.6%). The thrombolysis rate increased most rapidly in hospitals in the western region (absolute growth of 25.0%), despite having the lowest initial rate (19.1% in 2018). Moreover, at the study endpoint, the thrombolysis rate was comparable between secondary and tertiary hospitals (42.4% vs 41.0% in 2022) and between the western and eastern regions (44.1% vs 41.0% in 2022).

DISCUSSION

To date, there has been no extensive research focusing on IVT in Chinese patients over 80 years who had an ischaemic stroke. In this large cohort study, drawn from a nationwide stroke registry, we observed that alteplase treatment in patients over 80 years old led to improved functional outcomes at discharge when compared with those who did not receive alteplase, without an increase in in-hospital mortality, despite a higher risk of sICH. Few studies have directly evaluated the efficacy and safety of IVT in older populations. Our results align with findings from the Safe Implementation of Treatments in Stroke–International Stroke Thrombolysis Registry (SITS-ISTR) and the Virtual International Stroke Trials Archive (VISTA), the largest observational studies in this field. These studies included 29500 patients who had an ischaemic stroke who presented within 3 hours of symptom onset, of which, 3472 (11.8%) were over 80 years old. Sensitivity analyses in those studies demonstrated that patients receiving alteplase had significantly better functional outcomes at 3 months.²³ Specifically, the odds of achieving a mRS Score of 0–2 were 2.1 (95% CI, 1.7 to 2.5), and for an mRS of 0–1, the OR was 1.9 (95% CI, 1.5 to 2.3). Unlike those studies, our research examined patients treated within 4.5 hours of symptom onset and found that alteplase consistently resulted in better in-hospital outcomes across all ODT groups. These findings support the current Class IIA guidelines recommending thrombolytic therapy for elderly patients within the 3–4.5 hours of window, further reinforcing its use in patients over 80 years of age within 4.5 hours of symptom onset.

Our study found that 55.0% (n=4815) of elderly patients treated with alteplase had mRS scores of 0–2 at discharge, a significantly higher proportion than reported in the Baden-Wuerttemberg (BW) stroke registry. In the BW cohort, which involves patients aged 18 years and older who were treated within 7 days of symptom onset, the mRS 0–2 outcome was 32.0% for those aged 80–89 years (n=2849) and 17.0% for patients over 90 years (n=394).²⁴

For patients with ischaemic stroke aged >90 years, our study shows that thrombolytic therapy does not improve functional outcomes. This finding aligns with the results of the SITS-ISTR and VISTA study. The analysis demonstrated no statistically significant difference in 90-day functional outcomes (mRS 0–2) between the thrombolysis group (n=133) and the non-thrombolysis group (n=77) among patients aged 90–100 years (OR 1.2, 95% CI, 0.69 to 2.0). Given our large sample size (thrombolysis: n=606 vs non-thrombolysis: n=2084), we recommend that thrombolytic therapy for patients over 90 years old in China be considered with caution.

Although thrombolytic therapy for acute ischaemic stroke is linked to an elevated risk of sICH shortly after treatment, our study showed that the incidence of sICH in elderly patients treated with alteplase was 3.22 times higher compared with untreated patients.^{25–26} However, the sICH rate of 5% in our study was still lower than those reported in earlier studies, where rates ranged from 6.7% to 17.5%.^{7–24–27–28} This lower rate may be explained by the fact that our patients had lower baseline NIHSS scores, which correlates with a reduced risk of sICH.²⁴ In contrast, elderly patients treated with alteplase in randomised controlled trials (RCTs) had a higher average NIHSS Score (mean (SD): 13.3 (6.4))¹⁸ and several registry studies reported a median NIHSS of 14,^{7–24–29} potentially accounting for their higher sICH rates. Our study also indicated that IVT was not associated with an increase in short-term mortality among elderly patients who had a stroke, which is consistent with findings from individual analyses of seven RCTs.³⁰ This study reported no significant difference in mortality at 7 days between patients receiving alteplase and those on placebo (10.6% vs 7.8%, *p*=0.13), with similar outcomes for mortality within 90 days.

The rate of IVT use increased annually in both older and younger patient groups throughout the study period, with the average annual growth rate being higher in older patients compared with younger ones (12.5% vs 9.1%). This trend aligns with the increasing IVT rates seen in developed countries. However, our study found that the IVT rate for patients treated within 4.5 hours of stroke onset was still significantly lower than the 63.9% reported in the Get with the Guidelines–Stroke initiative in the USA.³¹ Specifically, in 2022, the IVT usage rate in elderly patients was 34.2%, indicating that nearly two-thirds of eligible patients aged over 80 did not receive thrombolysis, highlighting the need for further improvement in this area.

Subgroup analysis showed that patients with moderate stroke derived more benefit from IVT, which is consistent with prior studies indicating stroke severity as an independent predictor of thrombolysis outcomes. Patients with less severe strokes (NIHSS < 20) were shown to benefit more from IVT.³² While no evidence suggests that diabetes alters the efficacy of IVT, diabetic patients are generally linked to worse functional outcomes after thrombolysis.^{33–36} Our study also confirmed that diabetes

does not modify the effect of thrombolysis; however, patients without diabetes tend to have better functional outcomes. Interestingly, elderly patients with atrial fibrillation benefit more from thrombolytic therapy, which may be related to our primary focus on in-hospital outcomes. This warrants further investigation into the long-term effects of thrombolysis in patients over 80 years who had a stroke with atrial fibrillation. Additionally, our findings indicate that prior use of antithrombotic agents should not be a reason to withhold IVT with alteplase in patients over 80 years with acute ischaemic stroke.

Several limitations should be acknowledged when interpreting these findings. First, we lacked data on 90-day postdischarge outcomes. However, previous studies have shown that discharge disability status and ambulation are strong predictors of 90-day outcomes³⁷; suggesting that our discharge data may serve as reliable indicators. Second, as a retrospective, non-randomised study, there is potential for selection bias; however, we used the IPTW method to mitigate this issue. Finally, the study only included data from CSCA hospitals, which may not represent all hospitals in China. Nevertheless, the CSCA remains the largest stroke registry and quality improvement programme in China, including over 1 million patients who had an acute ischaemic stroke across 1751 hospitals, which provides a robust sample size for generalisation.

CONCLUSIONS

This nationwide, multicentre registry study evaluating the use of IVT in patients over 80 years who had an ischaemic stroke showed that alteplase treatment is beneficial for this population. Additionally, despite an increased incidence of sICH, there was no associated rise in in-hospital mortality. These findings further support the effectiveness of IVT with alteplase in elderly patients in China. While the rate of IVT use in older patients has increased each year, nearly two-thirds of eligible elderly patients who had a stroke still do not receive thrombolysis. Continued research is needed to better understand the medium-term and long-term outcomes of IVT in this age group.

Author affiliations

¹Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Fengtai, Beijing, China

²Department of Emergency, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China

³China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Fengtai, Beijing, China

⁴National Center for Healthcare Quality Management in Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Fengtai, Beijing, China

Acknowledgements We thank all participating hospitals, relevant clinicians, statisticians and imaging and laboratory technicians. We would like to thank Editage (www.editage.cn) for English language editing.

Contributors ZL taken responsibility for the overall content as the guarantor. CW and ZL had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis.

Funding This study was supported by grants 2022YFC2504902 and 2022YFC2504904 from the Ministry of Science and Technology of the People's Republic of China, grant Z200016 from the Beijing Natural Science

Foundation, grant 2018000021223ZK03 from Beijing Talents Project and grants Z201100005620010 and Z211100002921064 from the Beijing Municipal Committee of Science and Technology.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants. This study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the ethical review board of Beijing Tiantan Hospital (ethical approval number: KY2018-061-02). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Changsheng Li <http://orcid.org/0000-0002-6329-4080>

Hong-Qiu Gu <http://orcid.org/0000-0003-1608-1856>

Meng Wang <http://orcid.org/0000-0001-9678-4855>

Zimo Chen <http://orcid.org/0000-0003-0942-2448>

Qi Zhou <http://orcid.org/0000-0002-5697-2998>

Zixiao Li <http://orcid.org/0000-0002-4713-5418>

REFERENCES

- 1 Wu S, Wu B, Liu M, *et al*. Stroke in China: advances and challenges in epidemiology, prevention, and management. *Lancet Neurol* 2019;18:394–405.
- 2 Wang Y-J, Li Z-X, Gu H-Q, *et al*. China Stroke Statistics: an update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. *Stroke Vasc Neurol* 2022;7:415–50.
- 3 Li Z, Jiang Y, Li H, *et al*. China's response to the rising stroke burden. *BMJ* 2019;364:l879.
- 4 Feigin VL, Nguyen G, Cercy K, *et al*. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. *N Engl J Med* 2018;379:2429–37.
- 5 Tu W-J, Zhao Z, Yin P, *et al*. Estimated Burden of Stroke in China in 2020. *JAMA Netw Open* 2023;6:e231455.
- 6 Ma Q, Li R, Wang L, *et al*. Temporal trend and attributable risk factors of stroke burden in China, 1990–2019: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health* 2021;6:e897–906.
- 7 Ford GA, Ahmed N, Azevedo E, *et al*. Intravenous alteplase for stroke in those older than 80 years old. *Stroke* 2010;41:2568–74.
- 8 Fang EF, Xie C, Schenkel JA, *et al*. A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks. *Ageing Res Rev* 2020;64:101174.
- 9 National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. *N Engl J Med* 1995;333:1581–8.
- 10 Bluhmki E, Chamorro A, Dávalos A, *et al*. Stroke treatment with alteplase given 3.0–4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. *Lancet Neurol* 2009;8:1095–102.

- 11 Jauch EC, Saver JL, Adams HP. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2013;44:870–947.
- 12 Neurology Society of Chinese Medical Association, Cerebrovascular Disease Group. Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2014. *Chin J Neurol* 2015;48:246–57.
- 13 Warner JJ, Harrington RA, Sacco RL, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. *Stroke* 2019;50:3331–2.
- 14 Neurology Society of Chinese Medical Association, Cerebrovascular Disease Group. Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018. *Chin J Neurol* 2018;51:666–80.
- 15 Otite FO, Saini V, Sur NB, et al. Ten-Year Trend in Age, Sex, and Racial Disparity in tPA (Alteplase) and Thrombectomy Use Following Stroke in the United States. *Stroke* 2021;52:2562–70.
- 16 Yang J, Liang H, Song Y, et al. Analysis of the Efficacy and Safety of Recombinant Tissue Plasminogen Activator for Chinese Patients over 80 Years of Age with Acute Ischemic Stroke: A Pilot Study. *Neurosci Bull* 2016;32:202–3.
- 17 Chen Y, Li C-H, Wang Y-X, et al. Safety and Effectiveness of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in 80 Years and Older Acute Ischemic Stroke Patients. *Cell Biochem Biophys* 2015;72:883–8.
- 18 Wang Y, Li Z, Wang Y, et al. Chinese Stroke Center Alliance: a national effort to improve healthcare quality for acute stroke and transient ischaemic attack: rationale, design and preliminary findings. *Stroke Vasc Neurol* 2018;3:256–62.
- 19 Li F, Morgan KL, Zaslavsky AM. Balancing Covariates via Propensity Score Weighting. *J Am Stat Assoc* 2018;113:390–400.
- 20 Thomas LE, Li F, Pencina MJ. Overlap Weighting. *JAMA* 2020;323:2417.
- 21 Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. *Commun Stat Simul Comput* 2009;38:1228–34.
- 22 Gu H-Q, Yang X, Wang C-J, et al. Assessment of Trends in Guideline-Based Oral Anticoagulant Prescription for Patients With Ischemic Stroke and Atrial Fibrillation in China. *JAMA Netw Open* 2021;4:e2118816.
- 23 Mishra NK, Ahmed N, Andersen G, et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. *BMJ* 2010;341:c6046.
- 24 Reuter B, Gumbinger C, Sauer T, et al. Intravenous thrombolysis for acute ischaemic stroke in the elderly: data from the Baden-Wuerttemberg stroke registry. *Eur J Neurol* 2016;23:13–20.
- 25 Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. *Lancet* 2014;384:1929–35.
- 26 Whiteley WN, Emberson J, Lees KR, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. *Lancet Neurol* 2016;15:925–33.
- 27 Ringleb PA, Schwark C, Köhrmann M, et al. Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. *J Neurol Neurosurg Psychiatry* 2007;78:690–3.
- 28 Boulouis G, Dumont F, Cordonnier C, et al. Intravenous thrombolysis for acute cerebral ischaemia in old stroke patients ≥ 80 years of age. *J Neurol* 2012;259:1461–7.
- 29 Ahmed N, Lees KR, Ringleb PA, et al. Outcome after stroke thrombolysis in patients >80 years treated within 3 hours vs >3 –4.5 hours. *Neurology (Ecricon)* 2017;89:1561–8.
- 30 Bluhmki E, Danays T, Biegert G, et al. Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data. *Stroke* 2020;51:2322–31.
- 31 Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. *JAMA* 2014;311:1632–40.
- 32 Demchuk AM, Tanne D, Hill MD, et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. *Neurology (Ecricon)* 2001;57:474–80.
- 33 Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. *Eur Stroke J* 2021;6:LXII.
- 34 Lindley RI, Wardlaw JM, Whiteley WN, et al. Alteplase for acute ischemic stroke: Outcomes by clinically important subgroups in the third international stroke trial. *Stroke* 2015;46:746–56.
- 35 Nikneshan D, Raptis R, Pongmoragot J, et al. Predicting clinical outcomes and response to thrombolysis in acute stroke patients with diabetes. *Diabetes Care* 2013;36:2041–7.
- 36 Desilles J-P, Meseguer E, Labreuche J, et al. Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review. *Stroke* 2013;44:1915–23.
- 37 ElHabr AK, Katz JM, Wang J, et al. Predicting 90-day modified Rankin Scale score with discharge information in acute ischaemic stroke patients following treatment. *BMJ Neurol Open* 2021;3:e000177.